Gene Editing

Sector thesis

Gene editing is the science of precisely changing DNA in living cells—think of it as find-and-replace for the genetic code. The most famous tool is CRISPR, which works like molecular scissors, but there are other approaches too. The sector is interesting because we're moving from lab curiosity to actual treatments for diseases. Sickle cell, certain cancers, and inherited blindness are already seeing real-world results. The megatrend is simple: as the technology gets cheaper and more reliable, it becomes economically viable to treat diseases that were previously untreatable. This opens a massive market. Within gene editing, there are three main paths: CRISPR-based therapies (the most famous), base editing and prime editing (newer, potentially more precise methods), and ex vivo editing (editing cells outside the body, then putting them back—lower risk but more complex). Each has different companies betting on it, different timelines, and different regulatory hurdles. The biggest risks are real. First, these are early-stage treatments—many won't work, and some may have unexpected side effects we don't see until years later. Second, the regulatory path is uncertain; governments are still figuring out how to approve gene therapies safely. Third, manufacturing is hard; scaling up these treatments to treat millions of people is not solved yet. Fourth, cost: early gene therapies are extremely expensive, and insurance coverage is unpredictable. For a retail portfolio, this is a high-risk, long-term bet. You're not buying a mature business; you're betting on scientific progress. Watch for clinical trial results (does the treatment actually work?), regulatory approvals (is it safe enough?), and manufacturing progress (can they make it at scale?). Diversification matters here—pick a few companies across different editing approaches rather than betting everything on one technology.